Table 8.

Short version: statements pertaining upper gastrointestinal manifestations in MUTYH-associated polyposis

Statements	Level of evidence and agreement
MAP.UGM.1: Upper-GI tract surveillance is recommended in MAP patients.	LE: Low Agreement: 100% (SA 62%; A: 38%)
MAP.UGM.2: Upper GI surveillance by OGD should start from age 35 years.	LE: Low Agreement: 90% (SA 37%; A: 53%; 10%)
MAP.UGM.3: Upper GI surveillance in MAP should be adapted according to OGD findings, but not exceeding at interval 3 years. Polypectomy is recommended, regardless of polyp size.	LE: Low Agreement: 100% (SA 46%; A: 54%)

A, agree; D, disagree; GI, gastrointestinal; LE, level of evidence; MAP, MUTYH-associated polyposis; N, neutral; OGD, oesophagogastro-duodenoscopy; SA, strongly agree; SD, strongly disagree.